On April 18, 2019 Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, reported an oral presentation by Dr. Jo Brewer, VP of Platform Sciences, summarizing data from Adaptimmune’s off‑the‑shelf SPEAR T-cell program at the American Society of Gene & Cell Therapy (ASGCT) (Free ASGCT Whitepaper) Annual Meeting that will be held from April 29 to May 2, 2019 in Washington, DC (Press release, Adaptimmune, APR 18, 2019, View Source;p=RssLanding&cat=news&id=2395049 [SID1234535216]). Details on date and time of the presentation can be found below.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Oral presentation details:
Title: Differentiating T-Cells from Human induced pluripotent stem cells (hiPSCs) to Create Off-The-Shelf SPEAR T-Cell Therapies
Session title: Immunotherapy II
Session Date/Time: Thursday May 2, 2019 10:15 AM – 12:15 PM (EDT)
Presentation Time: 11:30am – 11:45am
Room: Heights Courtyard 1
Final abstract: #990, p. 460 (https://bit.ly/2PeMtDZ)